Jazz Pharmaceuticals to Present Preclinical Data on Pan-RAF Inhibitor at the 2022 American Association for Cancer Research (AACR) Annual Meeting

DUBLIN, March 8, 2022 /PRNewswire/ — Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that preclinical data on JZP815, an investigational next-generation pan-RAF kinase inhibitor, will be presented as a poster at the American Association for Cancer Research (AACR ) 2022 Annual Meeting of the April 8-13, 2022.

“With our preclinical collaboration partner, Redx Pharma, we look forward to presenting at the AACR our first preclinical data on JZP815, which has demonstrated that it selectively and potently inhibits mutant kinases A, B and CRAF, and has demonstrated a antitumor activity in RAS and RAF mutant xenograft models,” said Rob Iannone, MD, MSCE, Executive Vice President, Global Head of Research and Development, Jazz Pharmaceuticals. “The pan-RAF inhibitor program is part of a new class of next-generation precision oncology therapies that has the potential to benefit cancer patients with high unmet needs across several different solid tumors. We look forward to to advance JZP815 to the clinic to further evaluate the benefit it may have for appropriate patients.”

The abstract of the Jazz presentation – titled “JZP815, a potent and selective pan-RAF inhibitor, demonstrates efficacy in preclinical models of RAF and RAS mutant tumors” – and details of the 2022 AACR Annual Meeting are available here.

Activation of the mitogen-activated protein kinase (MAPK) pathway by oncogenic mutations in RAS and RAF is a frequent driver of cancer. Targeting specific components of the pathway may be a precise and rational way to deliver benefits to cancer patients with high unmet needs. RAF kinase proteins (ARAF, BRAF, CRAF) are major pathway components involved in MAPK signaling. Mutations in these critical signaling proteins lead to constitutive activation of the MAPK pathway and tumor growth.

JZP815 is a next-generation, preclinical-stage pan-RAF kinase inhibitor that was discovered and developed using state-of-the-art screening and medicinal chemistry methodologies. JZP815 is currently not approved for use anywhere in the world.

Jazz acquired JZP815 from Redx Pharma, and the two companies are collaborating on this preclinical research. Jazz plans to submit an IND for JZP815 this year. JZP815 is part of Jazz’s early-stage R&D pipeline focused on precision oncology in solid tumors.

About Jazz Pharmaceuticals plc
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) is a global biopharmaceutical company focused on innovating to transform the lives of patients and their families. We are committed to developing life-changing medicines for people with serious diseases, often with limited or no treatment options. We have a diverse portfolio of marketed drugs and new product candidates, from early to late-stage development, in neuroscience and oncology. In these therapeutic areas, we identify new options for patients by actively exploring small molecules and biologics, and through innovative delivery technologies and cannabinoid science. Jazz is headquartered in Dublin, Ireland and has employees worldwide, serving patients in nearly 75 countries. For more information, visit www.jazzpharmaceuticals.com and follow @JazzPharma on Twitter.

Caution Regarding Forward-Looking Statements
This press release contains forward-looking statements, including, but not limited to, statements relating to Jazz Pharmaceuticals’ belief in the potential of JZP815 to provide a potentially novel therapeutic option for several types of solid tumors; progressing JZP815 to the clinic and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals’ current plans, objectives, estimates, expectations and intentions and inherently involve significant risks and uncertainties. Actual results and timing of events could differ materially from those anticipated in these forward-looking statements due to these risks and uncertainties, which include, but are not limited to, the effective registration of JZP815 with the FDA and the launch of clinical tests ; launch and market new products; obtain and maintain adequate coverage and reimbursement for Company products; delays or problems in sourcing or manufacturing company products; and other risks and uncertainties affecting the company, including those described from time to time under “Risk Factors” and elsewhere in Jazz Pharmaceuticals’ Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including Jazz Pharmaceuticals Annual Report on Form 10-K for the fiscal year ended December 31, 2021 and future Jazz Pharmaceuticals filings and reports. Other risks and uncertainties not currently known to Jazz Pharmaceuticals may also affect Jazz Pharmaceuticals’ forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. The forward-looking statements herein are made only as of the date hereof or as of the dates indicated in the forward-looking statements, even if subsequently made available by Jazz Pharmaceuticals on its website or otherwise. Jazz Pharmaceuticals undertakes no obligation to update or supplement any forward-looking statements to reflect actual results, new information, future events, changes in its expectations or other circumstances that exist after the date on which the statements forecasts have been made.

Media Contact:
Kristin Bhavnani
Head of Global Corporate Communications
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 637 2141
USA +1 215 867 4948

Andrea N. Flynndoctorate
Vice President, Head, Investor Relations
Jazz Pharmaceuticals plc
[email protected]
Ireland +353 1 634 3211
USA +1 650 496 2717

SOURCE Jazz Pharmaceuticals plc

Comments are closed.